News

At the end of the 6-month, placebo-controlled treatment period, treatment with lemborexant at 5 mg or 10 mg resulted in statistically significant improvements compared to placebo in patient-reported sleep onset latency, subjective sleep efficiency, and subjective wake after sleep onset.

The phase 2 trial for the CGRP receptor agonist is planned for Q2 of 2019 after the intranasal treatment met its target therapeutic exposures in phase 1. Biohaven submitted an IND to the FDA in September 2018.

According to physician-reported data, the wearable PKG device provided data which resulted in an alteration in Parkinson management for 32% of patients.

The chief executive officer of C2N Diagnosis spoke about an investigational blood test used for screening of amyloid pathology in individuals being assessed for Alzheimer disease diagnosis.

The phase 1 trial assessed high doses of the therapy in 24 healthy volunteers, divvied up into 4 cohorts to receive doses, including 36 mg/kg, 60 mg/kg, 85 mg/kg, and 110 mg/kg. These data build upon the findings of the phase 2b CHANGE-MS trial.

The recall began in October 2018, was initiated due to a mislabeling on the pre-printed content on the infusion bag for lot ABD807. Thus far, there have been no reported adverse events related to this recall.

The Director of the Jefferson Headache Center spoke about migraine therapies that hold excitement and promise in the new year.

If the C2N brain amyloidosis test becomes FDA approved, this could be the first blood-based screening test to predict brain amyloid PET scan results in those with memory complaints or dementia.

Neurology News Network for the week of February 2, 2019.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how broaching the topic of SUDEP has gone from undiscussed to a guideline-mandated practice in epilepsy.

The chief scientific officer of Cortexyme detailed the findings of a study that suggested that Porphyromonas gingivalis plays a role as a driver of Alzheimer disease pathology.

The David M. Levy Professor of Neurology and director of the Center for Health and Technology at the University of Rochester Medical Center spoke about the projection for the future and what could be done to mitigate it.

Approximately 60% of the patients with ALS are already excluded from clinical trial participation at the day of diagnosis, but investigators think that 60% is an underestimate.

The regulatory agency determined that it was unable to approve the treatment in its present form, requesting additional information and analyses but no additional clinical studies.

The Independent Monitoring Committee’s interim analysis suggested that the treatment was unlikely to meet the trials’ primary end point of change from baseline in Clinical Dementia Rating-Sum of Boxes score.

The model showed that sporadic Alzheimer cells differentiated in an accelerated fashion in early development, as well as irregularities in the REST protein.

Data has suggested that patients with multiple sclerosis who have withdrawn from treatment with fingolimod (Gilenya, Novartis) can safely be treated effectively with alemtuzumab (Lemtrada, Sanofi Genzyme) or rituximab (Rituxan, Genentech/Biogen).

Despite the non-significant differences between groups, a slight trend toward a dementia risk reduction has led to the Alzheimer’s Association providing funds for a follow-up extension trial, dubbed SPRINT-MIND 2.0.

The Baldwin Keyes Professor of Neurology and director of the Jefferson Comprehensive Epilepsy Center at Thomas Jefferson University spoke about the trial of the Visualase MRI-guided laser ablation system and the unmet needs in epilepsy.

CAP-1002 is the only therapy to show reduction in myocardium scar and an improvement of localized cardiac function in late-stage Duchenne accompanied cardiomyopathy.

The mist-like nasal spray acts rapidly and is well tolerated and is formulated using Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action.

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the findings and the importance of discovering more about mechanisms of action.

The chief of the Division of Immunotherapy at the Northwestern University Feinberg School of Medicine discussed the results of the randomized clinical trial and the implications of this treatment in clinical practice.

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the future of epilepsy and shared which studies of the condition that he’s been keeping an eye on.

The director of Pediatric Epilepsy at Centennial Children's Hospital spoke about the need to increase epilepsy's awareness and the clinical development of several agents that he is keeping his eyes on.

The postgraduate epidemiology fellow at the Centers for Disease Control and Prevention discussed the data and what she and her colleagues found in their analyses of children with Tourette syndrome.

Nonmyeloablative hematopoietic stem cell transplantation showed less disease progression in relapsing multiple sclerosis patients after 1 year compared to a number of FDA-approved disease-modifying therapies.

Neurology News Network for the week of January 26, 2019.